TITLE

Rules for drug trials should be tightened, say experts

AUTHOR(S)
Kmietowicz, Zosia
PUB. DATE
August 2006
SOURCE
BMJ: British Medical Journal (International Edition);8/5/2006, Vol. 332 Issue 7562, p276
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers a news brief about a report by the British government's Commission on Human Medicines that says that new high-risk drugs in phase I studies should be given to a single person at a time with observation time between doses. Phase I studies are the first time drugs are tested in humans. These findings are in the wake of serious ailments in six volunteers in a trial of the drug, TGN1412.
ACCESSION #
21898772

 

Related Articles

  • Full Disclosure and Conflicts of Interest. Wechsler, Jill // Applied Clinical Trials;Jul2000, Vol. 9 Issue 7, p22 

    Focuses on efforts to increase safeguards for people participating in clinical trials in the United States. Concerns over the adequacy of investigator financial disclosure requirements; Call made by the Department of Health and Human Services for a clarification of policies to avoid conflicts...

  • Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. De Angelis, Catherine D.; Drazen, Jeffrey M.; Frizelle, Frank A.; Haug, Charlotte; Hoey, John; Horton, Richard; Kotzin, Sheldon; Laine, Christine; Marušić, Ana; Overbeke, A. John P. M.; Schroeder, Torben V.; Sox, Harold C.; Van Der Weyden, Martin B. // CMAJ: Canadian Medical Association Journal;6/21/2005, Vol. 172 Issue 13, p1700 

    Presents a statement released by the International Committee of Medical Journal Editors (ICMJE) regarding the registration of clinical trials. Goal of the ICMJE regarding clinical trials registration; Purpose of the suggested clinical trials registry.

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. Hanley, Bec; Truesdale, Ann; King, Andy; Elbourne, Diana; Chalmers, Iain // BMJ: British Medical Journal (International Edition);03/03/2001, Vol. 322 Issue 7285, p519 

    Conclusions: Consumer involvement in the design and conduct of controlled trials seems to be growing and seems to be welcomed by most researchers. Such involvement seems likely to improve the relevance to consumers of the questions addressed and the results obtained in controlled trials.

  • Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. Evans; Pocock; Lievre, Michel; Menard, Joel; Bruckert, Eric; Cogneau, Joel; Delahaye, Francois; Giral, Philippe; Leitersdorf, Eran; Luc, Gerald; Masana, Luis; Moulin, Philippe; Passa, Philippe; Pouchain, Denis; Siest, Gerard // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p603 

    Discusses premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. Reasons why some trials are discontinued prematurely by their sponsor for strategic reasons; How public financial and scientific participation in some trials and increasing the...

  • Monitoring and Ensuring Safety During Clinical Research. Morse, Michael A.; Califf, Robert M.; Sugarman, Jeremy // JAMA: Journal of the American Medical Association;3/7/2001, Vol. 285 Issue 9, p1201 

    Addresses concerns regarding the protection of human subjects in clinical trials. Description of the manner in which adverse event reporting might function to enhance safety; Role of data monitoring committees in using aggregate data from these reports; Problems that exist for institutional...

  • Intention-to-treat analysis: Protecting the integrity of randomization. Mahaniah, Kiame J.; Rao, Goutham // Journal of Family Practice;Aug2004, Vol. 53 Issue 8, p644 

    Randomization is a crucial part of most clinical trials. The purpose of randomization in a trial comparing 2 groups is to ensure that the groups differ only with respect to the interventions being compared. Randomization determines not only which treatment subjects receive, but also how the...

  • CONSORT statement: extension to cluster randomised trials. Campbell, Marion K.; Elbourne, Diana R.; Altman, Douglas G. // BMJ: British Medical Journal (International Edition);3/20/2004, Vol. 328 Issue 7441, p702 

    Offers a look at the effective reporting of randomized controlled trials. Guidelines in the Consolidated Standards of Reporting Trials (CONSORT) statement; Discussion of methodological issues in cluster randomized trials; Quality of reporting of cluster trials; Extension of CONSORT statement to...

  • A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Lene Thorsen; Kerry Courneya; Clare Stevinson; Sophie Fosså // Supportive Care in Cancer;Sep2008, Vol. 16 Issue 9, p987 

    Abstract Introduction  We reviewed physical activity (PA) studies in prostate cancer (PC) survivors investigating (a) the effects of PA on health outcomes, (b) the prevalence of PA, and (c) the determinants of PA. Materials and methods  A systematic search of the literature...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics